



Dkt. 50875-DA/JPW/MAF/DJK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Graham P. Allaway, et al.  
U.S. Serial No.: 09/888,938 Examiner:  
Filed : June 25, 2001 Group Art Unit: 1645  
For : METHODS FOR PREVENTING HIV-1 INFECTION OF  
CD4+ CELLS

1185 Avenue of the Americas  
New York, New York 10036  
April 16, 2003

Assistant Commissioner for Patents  
Washington, D.C. 20231

SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following references, which are listed on Form PTO-1449 attached hereto as **Exhibit A**. Copies of the references listed below as items 1-2 are attached hereto as **Exhibits B-C**, respectively, for the Examiner's review and consideration.

1. Broder, et al., (1996) "HIV and the 7-Transmembrane Domain Receptors", Pathobiology, 64(4), 171-179 (**Exhibit B**);
2. Dikic, (1996) "Regulation of HIV-1 Infection By Chemokine Receptors", Acta Med. Croatica, 50, 163-168 (**Exhibit C**).

These items were first cited in an Examiner's First Report for corresponding Australia Patent Application No. 35106/01.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone either of them at the

RECEIVED  
APR 23 2003  
TECH CENTER 1600/2900

Applicant : Graham P. Allaway, et al.  
U.S. Serial No.: 09/888,938  
Filed : June 25, 2001  
Page 2

number provided below.

The Examiner is respectfully requested to make each of these references of record in the present application by initialing and dating a copy of the PTO Form 1449 submitted as Exhibit A and returning the same to applicants' representative with the next Communication concerning this application.

Pursuant to 37 C.F.R. §1.97(b)(3), no fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is due, authorization is hereby given to charge the required amount of any such fee to Deposit Account No.03-3125.

Respectfully submitted,

*John P. White*

John P. White  
Registration No. 28,678  
Mark A. Farley  
Registration No. 33,170  
Attorneys for Applicant(s)  
Cooper & Dunham, LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

*John P. White*  
John P. White  
Reg. No. 28,678  
Mark A. Farley  
Reg. No. 33,170

Date

OIP  
APR 21 2003

Sheet 1 of 1

Form PTO-1450

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
2048/50875-F-PCT-USSerial No.  
09/460,216

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants  
Graham P. Allaway, et al.Filing Date  
December 13, 1999Group  
1648

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Broder, et al., (1996) "HIV and the 7-Transmembrane Domain Receptors", <u>Pathobiology</u> , 64(4), 171-179 ( <b>Exhibit B</b> )
	Dikic, (1996) "Regulation of HIV-1 Infection By Chemokine Receptors", <u>Acta Med. Croatica</u> , 50, 163-168 ( <b>Exhibit C</b> )

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED  
APR 23 2003  
TECH CENTER 1600/2900